California Public Employees Retirement System Buys 19,936 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

California Public Employees Retirement System grew its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 14.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 160,376 shares of the biopharmaceutical company's stock after purchasing an additional 19,936 shares during the period. California Public Employees Retirement System owned approximately 0.17% of Intra-Cellular Therapies worth $11,486,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Signaturefd LLC raised its stake in shares of Intra-Cellular Therapies by 85.7% in the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 239 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Intra-Cellular Therapies during the 3rd quarter valued at about $45,000. CI Investments Inc. raised its position in shares of Intra-Cellular Therapies by 1,191.6% in the 3rd quarter. CI Investments Inc. now owns 1,692 shares of the biopharmaceutical company's stock valued at $88,000 after acquiring an additional 1,561 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Intra-Cellular Therapies by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,465 shares of the biopharmaceutical company's stock worth $128,000 after purchasing an additional 1,207 shares in the last quarter. Finally, Covestor Ltd grew its stake in shares of Intra-Cellular Therapies by 64.9% during the 3rd quarter. Covestor Ltd now owns 2,518 shares of the biopharmaceutical company's stock worth $131,000 after acquiring an additional 991 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Robert W. Baird lifted their target price on Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an "outperform" rating in a research report on Wednesday, April 17th. Needham & Company LLC raised their target price on Intra-Cellular Therapies from $82.00 to $90.00 and gave the company a "buy" rating in a report on Monday, April 22nd. Royal Bank of Canada restated an "outperform" rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 3rd. Canaccord Genuity Group lifted their price target on Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a "buy" rating in a report on Tuesday, April 23rd. Finally, TD Cowen boosted their target price on Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $90.17.

Intra-Cellular Therapies Trading Down 3.3 %

Shares of Intra-Cellular Therapies stock traded down $2.39 during trading hours on Thursday, reaching $70.34. The company's stock had a trading volume of 1,233,766 shares, compared to its average volume of 933,934. Intra-Cellular Therapies, Inc. has a one year low of $45.50 and a one year high of $84.89. The company's 50 day simple moving average is $69.22 and its 200 day simple moving average is $65.25.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14. The company had revenue of $132.10 million during the quarter, compared to analysts' expectations of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business's revenue for the quarter was up 50.3% on a year-over-year basis. During the same period last year, the company posted ($0.45) earnings per share. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current year.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, EVP Suresh K. Durgam sold 6,450 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the transaction, the executive vice president now owns 16,170 shares of the company's stock, valued at $1,076,275.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intra-Cellular Therapies news, EVP Suresh K. Durgam sold 6,450 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the sale, the executive vice president now owns 16,170 shares of the company's stock, valued at approximately $1,076,275.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Sharon Mates sold 20,565 shares of the company's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at $68,490,649.89. The disclosure for this sale can be found here. Insiders sold 168,487 shares of company stock worth $11,364,950 over the last ninety days. 3.40% of the stock is currently owned by insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.